Annual results for 2013: Cash position strengthened to €41.3m as at December 31, 2013

• Successful €20.3 m private placement subscribed entirely by US-based specialist investors
• Stable cash burn
• Acquisition in February 2014 of anti-NKG2A, a Phase II-ready first-in-class checkpoint inhibitor
• IPH4102 on track to start Phase I early 2015

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug-candidates for cancer and inflammatory diseases, reports today its consolidated financial results for the year ended December 31, 2013. The consolidated financial statements are attached to this press release.

Hervé Brailly, Chief Executive Officer of Innate Pharma, commented: “We have advanced and consildated our pipeline. Not only have we continued to progress in 2013 with our partnered and proprietary programs, we also raised our visibility and attracted a new pool of investors. This has translated into increasing our cash position and our market valuation, providing new means to continue to build our pipeline in immuno-oncology, as exemplified by the recent acquisition of the anti-NKG2A, a Phase II ready, first-in-class antibody program.

We now have two clinical-stage immune-oncology assets, one partnered with Bristol-Myers Squibb, and a proprietary program, which we want to bring forward. In addition, we expect IPH4102 to be in clinic in early 2015 and we have a rich discovery and technology portfolio to fuel the pipeline further down the road, as exemplified by our newly disclosed first-in-class anti-MICA antibody program. With major catalysts in clinical development ahead of us in 2014 and 2015, this is definitely a very exciting period for Innate”.